SLC16A3 and cancer: This potent inhibitor of MCT1 showed a reduction in growth of different cell lines especially hematological types. Although the inhibitory effect, some types of cancers express both transporters MCT1 and MCT4, in this regard MCT4 may be continuing the lactate transport suggesting a resistance to the monotherapy